You are here: Industry Insights > DARPin

News List

Novartis and Molecular Partners commence Covid-19 treatment trial pharmaceutical-technology
May 31, 2021
Novartis and Molecular Partners have commenced Phase II/III EMPATHY clinical trial of a new DARPin therapeutic candidate, ensovibep (MP0420), to treat Covid-19.
Novartis, Molecular Partners to develop two DARPin Therapies for COVID-19 americanpharmaceuticalreview
November 06, 2020
Novartis and Molecular Partners announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP04
Novartis sets sights on potential COVID-19 antivirals from Molecular Partners pharmatimes
October 30, 2020
Swiss pharma company Novartis has inked an option and license agreement with Molecular Partners to develop, manufacture and commercialise the latter’s anti-COVID-19 DARPin programme.
AGC Biologics, Molecular Partners to Develop Anti-COVID-19 DARPin Program americanpharmaceuticalreview
July 20, 2020
AGC Biologics is partnering with clinical-stage biotech company Molecular Partners to develop a new class of custom-built protein therapeutics known as DARPin®.
AGC Biologics, Molecular Partners to Develop DARPin Anti-COVID-19 Program contractpharma
July 10, 2020
AGC Biologics will manufacture MP0420 at 100 liter and 1,000 liter scales for development and initial global supply.